Penn State College of Medicine researchers have discovered a new class of drugs that may keep a deadly form of skin cancer from becoming resistant to treatment.
Lauren Evoy Davis
Scientists from Dana-Farber Cancer Institute found that a compound that can reverse the function of innate immune system cells—to fight tumors rather than encourage growth—caused breast tumors in mice to shrink and withdraw from distant metastases.
Scientists have discovered that African American patients with triple-negative breast cancer who carry a specific biomarker, nKIFC1, experience a dismal prognosis.
Researchers have identified a protein that may respond to PI3K/mTOR inhibitors for patients with a specific type of uterine sarcoma.
A secondary concern of breast cancer is the risk of the cancer cells spreading to the bones, causing severe pain and affecting quality of life. But a new study has identified how bones get damaged and researchers from Huntsman Cancer Institute at the University of Utah are developing a new drug to mitigate this problem.
One of the confounding issues with treating patients with immunotherapy for hematologic diseases is the risk of relapse that can occur during and after treatment.
There is a lot of interest in a new treatment that kills approximately 90% of melanoma cancer cells, an astounding accomplishment for Richard Neubig, MD, PhD, who serves as chairperson of pharmacology toxicology at Michigan State University.
The US Food and Drug Administration has accepted the first Biologics License Application for durvalumab (MEDI4736) to treat patients with urothelial cancer (UC) for whom cisplatin failed to stop disease progression.
Researchers have developed a new computational method to better understand what goes on inside a breast cancer tumor.
One of the complications of multiple myeloma, a malignancy of plasma cells in the bone marrow, includes bone fractures and/or spinal cord compression. But a new treatment may offer bone protection to mitigate these issues.